

## SNMMI NEWSLINE

- 23N** Joint NIBIB/NCI/SNMMI Workshop on Directly Imaging Targeted Radionuclide Therapy Isotopes  
I. George Zubal and Jacek Capala
- 26N** DOE and HHS Certify Sufficient <sup>99</sup>Mo Supplies
- 26N** FDA Approves New <sup>68</sup>Ga Kit for Prostate Cancer PET
- 27N** SNMMI Leadership Update: SNMMI to Host Summits on Artificial Intelligence and Patient Access  
Richard L. Wahl
- 28N** Newsbriefs
- 30N** From the Literature

## DISCUSSIONS WITH LEADERS

- 169** A European Oncology Leader Looks at PSMA: A Conversation Between Silke Gillessen, Johannes Czernin, and Ken Herrmann  
Silke Gillessen, Johannes Czernin, and Ken Herrmann

## THE STATE OF THE ART

- 172** A Guide to ComBat Harmonization of Imaging Biomarkers in Multicenter Studies  
Fanny Orlhac, Jakoba J. Eertink, Anne-Ségolène Cottreau, José M. Zijlstra, Catherine Thieblemont, Michel Meignan, Ronald Boellaard, and Irène Buvat

## HOT TOPICS

- 180** Is It Too Soon to Know When It's LATE?  
Angela C. Rieger and Daniel H.S. Silverman

## FOCUS ON MOLECULAR IMAGING

- 183** Visualizing T-Cell Responses: The T-Cell PET Imaging Toolbox  
Chao Li, Chaozhe Han, Shao Duan, Ping Li, Israt S. Alam, and Zunyu Xiao

## STANDARD OF CARE

- 189** Management of Differentiated Thyroid Cancer: The Standard of Care  
Anca M. Avram, Katherine Zukotynski, Helen Ruth Nadel, and Luca Giovannella

## EDITORIAL

- 196** Managing a High-Specific-Activity Iobenguane Therapy Clinic: From Operations to Reimbursement  
Sophia R. O'Brien and Daniel A. Pryma

## ONCOLOGY

### Clinical

- 199** <sup>18</sup>F-FDG PET/CT Imaging Biomarkers for Early and Late Evaluation of Response to First-Line Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma  
Matthias R. Benz, Wesley R. Armstrong, Francesco Ceci, Giulia Polverari, Timothy R. Donahue, Zev A. Wainberg, Andrew Quon, Martin Auerbach, Mark D. Girgis, Ken Herrmann, et al.
- 205** <sup>131</sup>I-GD2-ch14.18 Scintigraphy to Evaluate Option for Radioimmunotherapy in Patients with Advanced Tumors  
Ying Zhang, Juergen Kupferschlaeger, Peter Lang, Gerald Reischl, Rupert J. Handgretinger, Christian la Fougère, and Helmut Dittmann

## THERANOSTICS

### Clinical

- 212** Detecting Fibroblast Activation Proteins in Lymphoma Using <sup>68</sup>Ga-FAPI PET/CT  
Xiao Jin, Maomao Wei, Shuailiang Wang, Guochang Wang, Yumei Lai, Yunfei Shi, Yan Zhang, Zhi Yang, and Xuejuan Wang
- 218** Efficacy and Safety of <sup>177</sup>Lu-DOTATATE in Lung Neuroendocrine Tumors: A Bicenter study  
Lamiaa Zidan, Amir Iravani, Kira Oleinikov, Simona Ben-Haim, David J. Gross, Amichay Meirovitz, Ophra Maimon, Tim Akhurst, Michael Michael, Rodney J. Hicks, et al.
- 226** Tumor Sink Effect in <sup>68</sup>Ga-PSMA-11 PET: Myth or Reality?  
Andrei Gafita, Hui Wang, Andrew Robertson, Wesley R. Armstrong, Raphael Zaum, Manuel Weber, Farid Yagubbayli, Clemens Kratochwil, Tristan R. Grogan, Kathleen Nguyen, et al.
- 233** aPROMISE: A Novel Automated PROMISE Platform to Standardize Evaluation of Tumor Burden in <sup>18</sup>F-DCFPyL Images of Veterans with Prostate Cancer  
Nicholas Nickols, Aseem Anand, Kerstin Johnsson, Johan Brynolfsson, Pablo Borrelli, Neil Parikh, Jesus Juarez, Lida Jafari, Mattias Eiber, and Matthew Rettig
- 240** Diagnostic Performance and Clinical Impact of <sup>68</sup>Ga-PSMA-11 PET/CT Imaging in Early Relapsed Prostate Cancer After Radical Therapy: A Prospective Multicenter Study (IAEA-PSMA Study)  
Juliano J. Cerci, Stefano Fanti, Enrique E. Lobato, Jolanta Kunikowska, Omar Alonso, Sebastian Medina, Fuad Novruzov, Thabo Lengana, Carlos Granados, Rakesh Kumar, et al.
- 248** ■ BRIEF COMMUNICATION. The European Association of Urology Biochemical Recurrence Risk Groups Predict Findings on PSMA PET in Patients with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy  
Liang Dong, Yun Su, Yinjie Zhu, Mark C. Markowski, Mei Xin, Michael A. Gorin, Baijun Dong, Jiahua Pan, Martin G. Pomper, Jianjun Liu, et al.

**253** **Kidney Doses in <sup>177</sup>Lu-Based Radioligand Therapy in Prostate Cancer: Is Dose Estimation Based on Reduced Dosimetry Measurements Feasible?**

Michael Mix, Tobias Renaud, Felix Kind, Ursula Nemer, Elham Yousetzadeh-Nowsha, Tumelo C.G. Moalosi, Aymen M. Ormrane, Philipp T. Meyer, and Juri Ruf

**Basic**

- 259** ■ **FEATURED BASIC SCIENCE ARTICLE. An Improved <sup>211</sup>At-Labeled Agent for PSMA-Targeted  $\alpha$ -Therapy**  
Ronnie C. Mease, Choong Mo Kang, Vivek Kumar, Sangeeta Ray Banerjee, Il Minn, Mary Brummet, Kathleen L. Gabrielson, Yutian Feng, Andrew Park, Ana P. Kiess, et al.

**INFECTIOUS DISEASE**

**Clinical**

- 268** ■ **INVITED PERSPECTIVE. Imaging in Post-COVID Lung Disease: Does <sup>18</sup>F-FDG PET/CT Have the Key?**  
Olivier Gheysens, Leïla Belkhir, and François Jamar
- 270** ■ **BRIEF COMMUNICATION. Evolution of <sup>18</sup>F-FDG PET/CT Findings in Patients After COVID-19: An Initial Investigation**  
Andrew Thornton, Francesco Fraioli, Simon Wan, Helen S. Garthwaite, Balaji Ganeshan, Robert I. Shortman, Raymond Endozo, Stefan Vöö, Irfan Kayani, Deena Neriman, et al.
- 274** **Incidental Findings Suggestive of COVID-19 Pneumonia in Oncologic Patients Undergoing <sup>18</sup>F-FDG PET/CT Studies: Association Between Metabolic and Structural Lung Changes**  
Cristina Gamila Wakfie-Corieh, Federico Ferrando-Castagnetto, Alba María Blanes García, Marta García García-Esquinas, Aída Ortega Candil, Cristina Rodríguez Rey, María Nieves Cabrera-Martín, Ana Delgado Cano, and José Luis Carreras Delgado

**CARDIOVASCULAR**

**Clinical**

- 280** **Comparing Semiquantitative and Qualitative Methods of Vascular <sup>18</sup>F-FDG PET Activity Measurement in Large-Vessel Vasculitis**  
Himanshu R. Dashora, Joel S. Rosenblum, Kaitlin A. Quinn, Hugh Alessi, Elaine Novakovich, Babak Saboury, Mark A. Ahlman, and Peter C. Grayson

**NEUROLOGY**

**Clinical**

- 287** **Dynamic Amyloid PET: Relationships to <sup>18</sup>F-Flortaucipir Tau PET Measures**  
Fabio Raman, Yu-Hua Dean Fang, Sameera Grandhi, Charles F. Murchison, Richard E. Kennedy, John C. Morris, Parinaz Massoumzadeh, Tammie Benzinger, Erik D. Roberson, and Jonathan McConathy

**Basic**

- 294** **Relative Strengths of Three Linearizations of Receptor Availability: Saturation, Inhibition, and Occupancy Plots**  
Javad Khodaii, Mostafa Araj-Khodaie, Manouchehr S. Vafae, Dean F. Wong, and Albert Gjedde
- 302** **<sup>11</sup>C-PiB and <sup>124</sup>I-Antibody PET Provide Differing Estimates of Brain Amyloid- $\beta$  After Therapeutic Intervention**  
Silvio R. Meier, Dag Sehlin, Sahar Roshanbin, Victoria Lim Falk, Takashi Saito, Takaomi C. Saido, Ulf Neumann, Johanna Rokka, Jonas Eriksson, and Stina Syvänen

**ENDOCRINOLOGY**

**Clinical**

- 310** ■ **FEATURED ARTICLE OF THE MONTH. <sup>68</sup>Ga-NODAGA-Exendin-4 PET/CT Improves the Detection of Focal Congenital Hyperinsulinism**  
Marti Boss, Christof Rottenburger, Winfried Brenner, Oliver Blankenstein, Vikas Prasad, Sonal Prasad, Paolo de Coppi, Peter Kühnen, Mijke Buitinga, Pirjo Nuutila, et al.

**SPECIAL CONTRIBUTION**

- 316** **RADAR Guide: Standard Methods for Calculating Radiation Doses for Radiopharmaceuticals, Part 1—Collection of Data for Radiopharmaceutical Dosimetry**  
Michael G. Stabin, Richard E. Wendt, and Glenn D. Flux

**LETTERS TO THE EDITOR**

- 323** **Commercially Competitive Vendor-Agnostic Image Reconstruction Could Be a Leap Forward for PET Harmonization**  
Adam L. Kesner
- 324** **A VISION of ALSYMPCA**  
Paulo Schiavom Duarte
- 324** **Reply: A VISION of ALSYMPCA**  
Oliver Sartor
- 325** **On Semiquantitative Methods for Assessing Vascular <sup>18</sup>F-FDG PET Activity in Large-Vessel Vasculitis**  
Eric Laffon and Roger Marthan
- 326** **Reply: On Semiquantitative Methods for Assessing Vascular <sup>18</sup>F-FDG PET Activity in Large-Vessel Vasculitis**  
Mark A. Ahlman, Roberto Maass-Moreno, and Peter C. Grayson

**DEPARTMENTS**

- 10A** **This Month in JNM**
- 19A** **Recruitment**
- 252** **Erratum**